SUMMIT, N.J., June 18, 2014 – Merck Animal Health today announced that Mark Engle, D.V.M, MS, has joined Merck Animal Health as a senior technical services manager for the Swine Business Unit. Dr. Engle received his doctor of veterinary medicine degree from Iowa State University and his master of science from the University of Minnesota. Dr. Engle has worked in private practice and swine farm management, as well as swine genetics companies. He was most recently with the Pig Improvement Company.
Dr. Engle holds leadership roles with the American Veterinary Medical Association, International Veterinary Medical Association, and American Association of Swine Veterinarians, as well as the National Institute for Animal Agriculture, National Pork Producers Council and U.S. Animal Health Association. He has made significant contributions to modern pork production, including work on food security, and swine disease monitoring, control and eradication.
Dr. Engle will be based in the Midwest and provide technical support for veterinary practices, swine production companies and the growing portfolio of Merck Animal Health swine products.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).